Achaogen Inc (NASDAQ:AKAO) major shareholder Robert W. Duggan purchased 20,000 shares of the firm’s stock in a transaction that occurred on Monday, March 12th. The stock was bought at an average cost of $11.39 per share, for a total transaction of $227,800.00. Following the purchase, the insider now owns 6,255,148 shares in the company, valued at $71,246,135.72. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Shares of Achaogen Inc (NASDAQ AKAO) opened at $11.57 on Thursday. The firm has a market capitalization of $490.49, a price-to-earnings ratio of -3.64 and a beta of 1.28. Achaogen Inc has a 52-week low of $9.83 and a 52-week high of $27.49. The company has a debt-to-equity ratio of 0.08, a quick ratio of 4.83 and a current ratio of 4.83.
Achaogen (NASDAQ:AKAO) last announced its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.21). Achaogen had a negative return on equity of 83.14% and a negative net margin of 1,124.10%. The company had revenue of $1.87 million for the quarter, compared to analyst estimates of $1.18 million. research analysts forecast that Achaogen Inc will post -3.5 EPS for the current year.
Several institutional investors have recently made changes to their positions in the stock. Alps Advisors Inc. grew its stake in shares of Achaogen by 12.8% during the third quarter. Alps Advisors Inc. now owns 41,593 shares of the biopharmaceutical company’s stock worth $663,000 after purchasing an additional 4,725 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Achaogen by 3.6% during the fourth quarter. Bank of New York Mellon Corp now owns 144,843 shares of the biopharmaceutical company’s stock worth $1,555,000 after purchasing an additional 4,999 shares during the period. TimesSquare Capital Management LLC grew its stake in shares of Achaogen by 0.5% during the fourth quarter. TimesSquare Capital Management LLC now owns 1,367,965 shares of the biopharmaceutical company’s stock worth $14,692,000 after purchasing an additional 6,300 shares during the period. Teachers Advisors LLC grew its stake in shares of Achaogen by 15.0% during the fourth quarter. Teachers Advisors LLC now owns 62,483 shares of the biopharmaceutical company’s stock worth $671,000 after purchasing an additional 8,137 shares during the period. Finally, Wells Fargo & Company MN grew its stake in shares of Achaogen by 34.3% during the third quarter. Wells Fargo & Company MN now owns 33,213 shares of the biopharmaceutical company’s stock worth $530,000 after purchasing an additional 8,483 shares during the period. 77.37% of the stock is owned by institutional investors and hedge funds.
Several analysts recently commented on the company. Leerink Swann reaffirmed an “outperform” rating on shares of Achaogen in a research note on Sunday, March 4th. William Blair reiterated an “outperform” rating on shares of Achaogen in a research report on Wednesday, February 28th. HC Wainwright cut their price objective on Achaogen from $31.00 to $29.00 and set a “buy” rating for the company in a research report on Thursday, March 1st. Stifel Nicolaus cut their price objective on Achaogen from $27.00 to $23.00 and set a “buy” rating for the company in a research report on Wednesday, February 28th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $20.00 price objective (down previously from $29.00) on shares of Achaogen in a research report on Wednesday, February 28th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. Achaogen has an average rating of “Buy” and an average price target of $24.10.
TRADEMARK VIOLATION WARNING: “Achaogen Inc (AKAO) Major Shareholder Robert W. Duggan Buys 20,000 Shares” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/03/15/achaogen-inc-akao-major-shareholder-robert-w-duggan-buys-20000-shares.html.
Achaogen Company Profile
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.